Satisfying the need for new pharmaceuticals

In order to combat disease, the pharmaceutical industry is constantly on the lookout for new and effective pharmaceutical and medical technology products. However, reduction in research productivity of major pharmaceutical companies now means that many new products have to be licensed in from small companies active within the biosciences. The lack of product pipelines of big pharma is our business opportunity.

Lund University Bioscience AB (LU Bio) was established to help satisfy the need to transform high-end research results and innovations into attractive business propositions through supporting researchers. We are an early-stage investor who provides both capital and industrial development expertise to enable a fast and efficient development of bioscience inventions.

Creating focused portfolio companies

Our investment strategy is to invest in innovations or projects needing start-up, early-stage or early-expansion capital. We aim to develop high-growth, high-technology and well-focused portfolio companies with the ability to create dominant and defensible market positions.

Although the primary geographical focus is southern Sweden LU Bio may invest in the entire the Nordic region.